Alkem Reduces Prices of Denuril, Brand of Denosumab by 30% for the Treatment of Osteoporosis in Postmenopausal Women MD Brand Connect16 Jan 2024 12:00 PM ISTOne of India's leading drug makers, Alkem Labs, has recently announced the reduction in the price of Denosumab injection sold under the brand name...
Include Ankle Brachial Index test to exclude peripheral artery disease: CDSCO Panel Tells Lupin on Denosumab PK/PD study Dr. Divya Colin2 Dec 2023 6:00 PM ISTNew Delhi: The drug major Lupin has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Denosumab effective in improving BMD and microarchitecture in rheumatoid arthritis Jacinthlyn Sylvia7 Sept 2023 9:30 AM ISTIn a recent study, a pre-specified exploratory analysis has shed light on the beneficial effects of denosumab on bone mineral density (BMD) and bone...
Lupin Gets CDSCO Panel Nod To study osteoporosis drug Denosumab Dr. Divya Colin4 Aug 2023 6:00 PM ISTNew Delhi: The drug major Lupin has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Denosumab and zoledronic acid therapy improves BMD in periprosthetic bone Jacinthlyn Sylvia20 Jun 2023 9:30 AM ISTA new study by Xiao Li and team showed that denosumab and zoledronic acid (ZA) are effective treatments against decline in periprosthetic bone mineral...
EMA accepts marketing authorization applications for proposed biosimilar Denosumab: Sandoz Ruchika Sharma28 May 2023 10:00 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
Denosumab may lower risk of type 2 diabetes in adults with osteoporosis Dr. Mahalakshmi Sivashankaran25 April 2023 11:15 AM ISTChina: A new study published in the BMJ: British Medical Journal suggests that denosumab, a medication used to treat osteoporosis, may have an added...
USFDA accepts Biologics License Application for proposed biosimilar denosumab: Sandoz Ruchika Sharma7 Feb 2023 10:15 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
Denosumab slows progression of erosive osteoarthritis of hand Jacinthlyn Sylvia26 Nov 2022 7:45 AM ISTA new study conducted by Ruth Wittoek and team showed that denosumab clearly modifies the structure of erosive hand osteoarthritis (OA), resulting in...
Dialysis patients receiving denosumab have increased risk of severe hypocalcemia, warns FDA Jacinthlyn Sylvia25 Nov 2022 7:30 PM ISTInterim findings from an ongoing safety trial of Denosumab (Prolia) in patients with severe renal disease revealed an elevated risk of hypocalcemia,...
Biocon Biologics collaborates with Yoshindo to commercialize bUstekinumab, bDenosumab in Japan Ruchika Sharma17 Oct 2022 2:30 PM ISTDenosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines Ruchika Sharma7 Sept 2022 11:45 AM ISTThis agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three...
